CL2022000319A1 - Derivados de amidas híbridas de anfotericina b - Google Patents

Derivados de amidas híbridas de anfotericina b

Info

Publication number
CL2022000319A1
CL2022000319A1 CL2022000319A CL2022000319A CL2022000319A1 CL 2022000319 A1 CL2022000319 A1 CL 2022000319A1 CL 2022000319 A CL2022000319 A CL 2022000319A CL 2022000319 A CL2022000319 A CL 2022000319A CL 2022000319 A1 CL2022000319 A1 CL 2022000319A1
Authority
CL
Chile
Prior art keywords
amphotericin
derivatives
amide derivatives
amides
hybrid
Prior art date
Application number
CL2022000319A
Other languages
English (en)
Inventor
Jiabao Zhang
Su Yan
Martin D Burke
Arun Maji
Yong Nian
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of CL2022000319A1 publication Critical patent/CL2022000319A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se divulgan derivados C16 amida de C2’-epi-anfotericina B (C2’epiAmB) y anfotericina B (AmB), caracterizados por presentar una eficacia clínica mejorada con una toxicidad reducida en comparación con la AmB. También se divulgan composiciones farmacéuticas que comprenden cualquier tipo de los derivados C16 amida, y métodos terapéuticos para usar los derivados C16 amida; y métodos para elaborar los derivados C16 amida de la C2’-epi-anfotericina B.
CL2022000319A 2019-08-08 2022-02-07 Derivados de amidas híbridas de anfotericina b CL2022000319A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962884464P 2019-08-08 2019-08-08
US201962951753P 2019-12-20 2019-12-20

Publications (1)

Publication Number Publication Date
CL2022000319A1 true CL2022000319A1 (es) 2022-10-21

Family

ID=74503735

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000319A CL2022000319A1 (es) 2019-08-08 2022-02-07 Derivados de amidas híbridas de anfotericina b

Country Status (12)

Country Link
US (1) US20230016424A1 (es)
EP (1) EP4009985A4 (es)
JP (1) JP2022543420A (es)
KR (1) KR20220071185A (es)
CN (1) CN114555094A (es)
AU (1) AU2020325163A1 (es)
BR (1) BR112022001866A2 (es)
CA (1) CA3149916A1 (es)
CL (1) CL2022000319A1 (es)
IL (1) IL290289A (es)
MX (1) MX2022001678A (es)
WO (1) WO2021026520A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192248A1 (en) * 2020-08-10 2023-06-14 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin b
CN115536716A (zh) * 2021-06-29 2022-12-30 中国科学院上海药物研究所 两性霉素b半合成衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122086B1 (en) * 1979-04-09 1982-06-30 Politechnika Gdanska Process for preparing amides of antibiotics from the group of polyene macrolides and their derivativesvykh makrolidov i ikh proizvodnykh
FR2776927B1 (fr) * 1998-04-07 2002-07-05 Univ Paris Curie Compositions pour la vectorisation de molecules
US6664241B2 (en) * 2000-05-31 2003-12-16 Micrologix Biotech Inc. Water-soluble amide derivatives of polyene macrolides and preparation and uses thereof
MX365184B (es) * 2010-12-21 2019-05-21 Centro De Investig Y De Estudios Avanzados Del I P N Nuevos compuestos analogos de la anfotericina y composiciones farmaceuticas que los contienen.
WO2013186384A1 (en) * 2012-06-15 2013-12-19 Blirt S.A. N-substituted second generation derivatives of antifungal antibiotic amphotericin b and methods of their preparation and application
JP7240811B2 (ja) * 2015-04-15 2023-03-16 スファンガ セラピューティクス インコーポレイテッド アムホテリシンｂの誘導体
US10322187B2 (en) * 2015-08-10 2019-06-18 Lehigh University Reduced toxicity molecular conjugates of anti-fungal agents

Also Published As

Publication number Publication date
EP4009985A4 (en) 2023-09-06
US20230016424A1 (en) 2023-01-19
WO2021026520A1 (en) 2021-02-11
MX2022001678A (es) 2022-05-18
CA3149916A1 (en) 2021-02-11
IL290289A (en) 2022-04-01
CN114555094A (zh) 2022-05-27
EP4009985A1 (en) 2022-06-15
JP2022543420A (ja) 2022-10-12
AU2020325163A1 (en) 2022-03-03
KR20220071185A (ko) 2022-05-31
BR112022001866A2 (pt) 2022-03-29

Similar Documents

Publication Publication Date Title
DOP2022000278A (es) Inhibidores de cisteína proteasas y sus métodos de uso
CL2020002511A1 (es) Compuestos heterocíclicos como inmunomoduladores.
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
DOP2022000124A (es) Derivados de pirazolilo útiles como agentes anticancerígenos
CL2022000319A1 (es) Derivados de amidas híbridas de anfotericina b
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
EA201991403A1 (ru) Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
ECSP088412A (es) Derivados de pirazina como moduladores de canal de sodio en el tratamiento del dolor
CY1120530T1 (el) Απο του στοματος χορηγησιμη φαρμακευτικη συνθεση
DOP2023000037A (es) Compuestos fosfolípidos y usos de los mismos
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
UY38304A (es) Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
DOP2021000028A (es) Formulaciones de dendrímeros
PA8546201A1 (es) Agentes antibacterianos
CO2022017895A2 (es) Inhibidores de cisteína proteasas y sus métodos de uso
MX2023001649A (es) Derivados de amida hibrida de anfotericina b.